

Overview of DTT's Novel Tools and Approaches Program

Erik J. Tokar, PhD Leader, Stem Cell Toxicology Group Mechanistic Toxicology Branch Division of Translation Toxicology, NIEHS

> ICCVAM Public Forum May 21st, 2024

National Institutes of Health • U.S. Department of Health and Human Services



- DTT Organization
- Overview of Novel Tools and Approaches (NTA) Program
 - What it is and what we do
 - Portfolio
- Examples of projects in NTA-PMT portfolio
 - PSC-based cardiac and neural model systems
 - cfDNA in organoid models
 - Dual reporter line for neurological disorders: Parkinson's Disease



Division of Translational Toxicology

- Branches
 - Systems Toxicology
 - Predictive Toxicology
 - Cellular and Molecular Pathology
 - Integrated Health and Assessment
 - Mechanistic Toxicology

- Programs / Strategic Areas of Focus
 - Exposure-based
 - Health Effects Innovations
 - Responsive Research
 - Strengthening Capabilities
 - NTA is here



What is the NTA Program?

- Different than most other DTT programs:
 - NTA is not focused on a specific type of disease or exposure
 - NTA is 1 of 2 programs that provides special capabilities to DTT

Health Effects Innovation Programs	Exposure-based Research Programs	esponsive Research Programs
Cardiovascular	Combined Exposures and Mixtures	Emerging Contaminants and Issues of Concern
Carcinogenicity	Consumer Products and Therapeutics	Safe and Sustainable Alternatives
Developmental Neurotoxicity	Occupational and Inhalation Exposures	
Strengthening Capabilities Programs	Scientific Cyberinfastructure	
Novel Tools and Approaches		Approaches



What Does the NTA Program Do?

- Identify new and novel approaches that may improve DTT science by:
 - Increasing testing throughput
 - Increasing speed of data acquisition from years to weeks
 - Increasing data accuracy and precision
 - Providing more in-depth analyses: molecular mode of action (MoA) and benchmark dose (BMD)
 - Enhancing human relevance of DTT studies







69 total projects in our portfolio

Bioassays and Biological Systems

3D Liver Models Neural Spheroids






Kidney Organoids Embryoid Bodies



Zebrafish






5-Day Rat Assay



Novel Applications in Toxicology


Metabolomics

In Vitro Phenotype Screening





Duplex Sequencing





Examples of Projects in the NTA Portfolio

Pluripotent Stem Cell (PSC)-based Model Systems




- Effects of environmental chemicals on developing embryos are relatively understudied
 - Lack of robust models that recapitulate human organogenesis
- Current in vivo modeling systems
 - Labor intensive, costly, time-consuming
- hPSCs offer an excellent opportunity to study developmental toxicity
 - Physiologically relevant, rapid, high-throughput
 - Mimic events in embryogenesis, organogenesis
 - Study defined stages of development \rightarrow windows of susceptibility
 - Fewer animals



Components of Our Model Systems

Cardiac model shown






Embryoid Body (EB) Model

• Screening for teratogens



Embryoid Bodies (EBs) for Developmental Toxicity






PSC-based Cardiac Model System


Early-life Development in Presence of Toxicants



Cadmium Inhibits Cardiomyocyte Formation

- Mesoderm induction (Day 0-2) stage:
 - Inhibition as low as 0.1 μM
- Cardiac induction (Day 2-4) stage:
 - No inhibition
- As had different window of susceptibility
 - Similar endpoints with Cd
 - Inhibition during cardiac but not mesoderm induction stage











Role of Histone Methylation During Cd Inhibition


- Genes, TFs associated with mesoderm and cardiomyocytes downregulated (not shown)
- H3K27me3: marker of inactive/repressive chromatin
- H3K4me3: marker of active promoters
- UNC1999 targets EZH2, specifically suppresses H3K27me3/2
 - Removed Cd ability to inhibit differentiation to cardiomyocytes





Cd Represses Cardiac Organoid Function





Wu X ... Hu, G, Tokar EJ, *Environ Health Perspect* (2022) 130(11):117002




Cell-free DNA (cfDNA) in Organoid Models

Neural model

National Institutes of Health • U.S. Department of Health and Human Services



- Cell-free DNA (cfDNA)
 - Much recent interest as a clinical biomarker
 - Prenatal screening, fetal gender, cancer screening, etc.
 - Limited understanding of changes during differentiation, organogenesis, toxic insult








Isolation of cfDNA from Cerebral Organoids


- Low concentrations
 - ≤ 1 ng/ul
- Fragment analysis
 - Majority are ~160 bp
- Mitochondrial and nuclear genes
 ddPCR
- cfDNA of both mitochondrial and nuclear origin is released in quantities sufficient for downstream analyses





WGS to Characterize cfDNA from Cerebral Organoids

- Gene Ontology analysis
 - Neurodevelopment and brain structure/organization
- Disease Ontology analysis
 - Intellectual disability and autism
- cfDNA that is relevant to brain tissue and human neurological disorders or development
- Future:
 - Human plasma/CSF
 - Toxicant-exposed organoids
 - Patient-derived iPSC lines/models






Dual Reporter Model System for Neurological Disorders


• Parkinson's Disease




- Dopaminergic (DA) neurons play key roles in neurological disorders (e.g. Parkinson's Disease)
- CRISPR gene-editing technique used to insert fluorescent markers
 - GFP for Nestin neural stem cells
 - mScarlett for Tyrosine Hydroxylase DA neurons
- Easy & rapid imaging of different stages of differentiation/development
- Monitor formation of neural stem cells and dopaminergic neurons



Embryonic Stem Cells



Neural Stem Cells



Dopaminergic Neurons





- Several useful model systems for improving DTT science (developmental toxicity)
 - EB, cardiac, neural, reporter line for monitoring DA neurons
- Address tasks assigned to NTA
 - High(er)-throughput screening
 - Rapid data acquisition
 - Investigations into mechanisms
 - Enhance human relevance
 - Fewer animals
- These model systems offer great opportunity for studying effects of early-life exposures on development and later-life disease



Current NTA Program Members

- David Crizer, PhD (PMT Lead)
- Rachel Frawley
- Georgia Roberts, PhD
- Kristine Witt, PhD
- Vesna Chapppell, PhD
- Erik Tokar, PhD
- Darlene Dixon, PhD (ExMT Liaison)

Stem Cell Tox Group

- Brian Silver, PhD
- Carri Murphy
- Xian Wu, PhD (now at ECU)
- Ian Chen, PhD (now at EPA DC)
- Anna Kreutz, PhD (now at Inotiv)
- Justin Gutkowski (now at NICHD)



Thank You!